Palisade Bio Revenue

Revenue (ttm)

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

Market Cap

270.00M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	-	-	-
Dec 31, 2023	250.00K	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	-	-	-
Dec 31, 2020	-	-	-
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2018	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
UnitedHealth Group	422.82B
Johnson & Johnson	92.15B
Merck & Co.	63.62B
AbbVie	58.33B
AstraZeneca	56.50B
Novartis AG	55.19B
Eli Lilly and Company	53.26B
Novo Nordisk	49.11B

Revenue Rankings

PALI News

2 days ago - Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations - GlobeNewsWire
10 days ago - Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD) - GlobeNewsWire
17 days ago - Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewsWire
20 days ago - Palisade Bio Announces Cancellation of Special Meeting of Stockholders - GlobeNewsWire
27 days ago - Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option - GlobeNewsWire
4 weeks ago - Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - GlobeNewsWire
4 weeks ago - Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum - GlobeNewsWire
6 weeks ago - Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data - GlobeNewsWire

More News